Clinical trials expand options for lung cancer patients
November 22, 2017
For people with advanced lung cancer, clinical trials open up new treatment options and offer access to promising new therapies. At Providence Cancer Institute, 20 studies of novel lung cancer therapies are open to patients now.
Two recently opened studies explore the potential of combined therapies, including immunotherapies, to improve results for patients with advanced non-small cell lung cancer:
Phase 1b/Study of VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer (CLASSICAL – Lung Study)
In preclinical studies, the combination of VX15/2503, an anti-semaphorin 4D antibody, and the PD-L1-blocking antibody avelumab showed potential for synergy in eradicating tumors. Providence Cancer Institute is one of three sites in the United States offering this trial. Read more about this study.
A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The "DURGA" Trial)
This study explores the anti-tumor vaccine viagenpumatucel-L in combination with other strategies to provoke the immune system to target tumors in patients with incurable or metastatic non-small cell lung cancer. Combining viagenpumatucel-L with anti-PD-1 agents may enhance the vaccine's anti-tumor activity while prolonging or increasing the efficacy of the checkpoint inhibitor. Providence is one of seven sites in the United States participating in this trial.
Multidisciplinary lung cancer management
The Providence Thoracic Oncology Program emphasizes a multidisciplinary approach to cancer management. Our clinical trials program offers a broad array of innovative clinical research, including studies of new surgical techniques, radiation, chemotherapy, targeted therapy and immunotherapy agents, and tissue banking.
Rachel Sanborn, M.D., co-director of the program, is the lead investigator of the two featured studies. Her research focuses on studying new agents or combinations of treatments for lung cancer, mesothelioma and other thoracic tumors.
See more studies
See all lung cancer studies currently open to patients.
See all studies in all cancer types (more than 150 studies are currently open) at Providence Cancer Institute.